Manufacturing Plasmid DNA

摘要

The concept of gene therapy is F far from new, with initial studies performed over 20 years ago (l). However, in the past few years an explosion of interest in this area has gone beyond initial regenerative approaches using viral vectors. Interest isnow moving increasingly into potential use of T cells modified using recombinant viral vectors for immunotherapy applications. Such therapies are based on using either adenoassociated virus (AAV) or lentivirus (l), both vectors being frequently generated through transient expression routes based on plasmid DNA as a starting material.